Beckman Coulter Introduces Latest Innovations in Clinical Diagnostics
Posted on 31 Jul 2024
Beckman Coulter, Inc. (Brea, CA, USA) is hosting in-booth presentations at ADLM 2024 where visitors can see its latest offerings in digital hematology, high-sensitivity immunoassay testing and more.
For modern clinical laboratories with heavy workloads, efficiency, and high-quality results are the most valuable characteristics to consider in automated hematology. Beckman Coulter’s hematology analyzers and laboratory solutions are designed to go beyond the efficiency that’s expected and deliver intelligent efficiency. At ADLM 2024, Beckman Coulter is highlighting the small yet sophisticated DxH 500 hematology analyzer that delivers a high-quality CBC and full 5-part differential with only 12 μL of blood. Also featured is the DxH 900 hematology analyzer that delivers accurate and high-confidence results on the first run alongside the DxH Slidemaker Stainer II (SMS II) which prepares slides automatically based on orders received from the LIS.
Among its innovations in biomarkers, Beckman Coulter is showcasing Monocyte Distribution Width (MDW), the only regulatory-cleared hematological biomarker that helps to establish the risk of severe infection and sepsis in adult patients in the emergency department. MDW is a measure of increased morphological variability of monocytes in response to bacterial, viral or fungal infections. MDW is reported automatically as part of a routine CBC with a Differential test using the Early Sepsis Indicator (ESId) application, which enables automatic reporting with no workflow changes or need to order an additional test.
Additionally, Beckman Coulter is featuring the DxI 9000 high-throughput, high-sensitivity immunoassay analyzer designed to power lab performance across health systems. The DxI 9000 analyzer innovations address today’s speed, reliability, reproducibility, quality, and menu expansion demands. At the same time, the novel Lumi-Phos PRO Substrate has shown the capability to develop increasingly sensitive and clinically relevant assays, ensuring the system can meet the healthcare needs of tomorrow. Beckman Coulter is highlighting its new DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay analyzer that incorporates recently the introduced DxC 500 AU chemistry analyzer technology with Six Sigma performance. Utilizing Beckman Coulter’s common reagents and consumables across its scalable clinical chemistry and immunoassay portfolio, the DxC 500i Analyzer enables commutable patient results, offering hospitals and healthcare networks strategic benefits in patient care and inventory management.
Related Links:
Beckman Coulter, Inc.
